Home2020/06 June 12, 2020 -

https://mysicklefamilyllc.com/wp-content/uploads/2020/06/shutterstock_251672251-1000x480@2x.jpeg

I recently was admitted to the hospital during a sickle cell crisis and because of suspected COVID-19. My experience was harrowing. I have experienced many things as a sickle cell disease patient. I have had pneumonia more frequently than I can remember, suffered collapsed lungs, had deep vein thrombosis and pulmonary embolisms, spent weeks on end in intensive care, and been intubated a number of times. But this latest admission was the most traumatic of...

https://mysicklefamilyllc.com/wp-content/uploads/2020/03/shutterstock_294841127-1280x720.jpg

Global Blood Therapeutics (GBT) will ask the U.S. Food and Drug Administration (FDA) to allow children with sickle cell disease (SCD), ages 4 to 11, to also be treated with Oxbryta (voxelotor). The company announced plans to file an application requesting extended approval after a Type B meeting with FDA officials. “We are pleased to have agreed with the FDA on a potential path forward to expand the use of Oxbryta in younger children, and we look forward to submitting...